Odiparcil

Phase 2Completed
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mucopolysaccharidosis VI

Conditions

Mucopolysaccharidosis VI

Trial Timeline

Dec 30, 2017 → Oct 22, 2019

About Odiparcil

Odiparcil is a phase 2 stage product being developed by Inventiva for Mucopolysaccharidosis VI. The current trial status is completed. This product is registered under clinical trial identifier NCT03370653. Target conditions include Mucopolysaccharidosis VI.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03370653Phase 2Completed

Competing Products

20 competing products in Mucopolysaccharidosis VI

See all competitors
ProductCompanyStageHype Score
anakinraSwedish Orphan BiovitrumPhase 1/2
40
laronidaseSanofiApproved
84
LaronidaseSanofiApproved
84
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 2
51
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
84
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)SanofiPhase 1/2
40
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
76
rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
76
Aldurazyme + Aldurazyme + placeboSanofiPhase 3
76
LaronidaseSanofiApproved
84
JR-141JCR PharmaceuticalsPhase 2/3
64
JR-441 + JR-441 + JR-441JCR PharmaceuticalsPhase 1/2
40
JR-446JCR PharmaceuticalsPhase 1/2
40
JR-171JCR PharmaceuticalsPhase 1/2
40
JR-141JCR PharmaceuticalsPhase 2
51
JR-141 + Idursulfase + JR-141 or IdursulfaseJCR PharmaceuticalsPhase 3
76
JR-141JCR PharmaceuticalsPhase 3
76
JR-171 (lepunafusp alfa)JCR PharmaceuticalsPhase 1/2
40
JR-141JCR PharmaceuticalsPhase 1/2
40
JR-141JCR PharmaceuticalsPhase 2/3
64